연구동향 분석
박사

Transarterial chemoembolization with sorafenib in VX2 tumor model of rabbit liver: pharmacokinetics and antitumor effect = 토끼 VX2 간종양 모델에서 소라페닙을 이용한 경동맥화학색전술: 약동학 및 항종양 효과

김경민 2016년

논문상세정보
인용/피인용
' Transarterial chemoembolization with sorafenib in VX2 tumor model of rabbit liver: pharmacokinetics and antitumor effect = 토끼 VX2 간종양 모델에서 소라페닙을 이용한 경동맥화학색전술: 약동학 및 항종양 효과' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료과학 약
  • Sorafenib
  • VX2 tumor
  • chemoembolization
  • hepatocellular carcinoma
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
4,203 0

0.0%

' Transarterial chemoembolization with sorafenib in VX2 tumor model of rabbit liver: pharmacokinetics and antitumor effect = 토끼 VX2 간종양 모델에서 소라페닙을 이용한 경동맥화학색전술: 약동학 및 항종양 효과' 의 참고문헌

  • Xu W, Kwon JH, Moon YH, et al. (2014) Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF- 1alpha pathway in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol, 140(9):1507-1515
  • Xu M, Zheng YL, Xie XY, et al. (2014) Sorafenib blocks the HIF- 1alpha/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells. DNA Cell Biol, 33(5):275-281
  • Wu XZ, Xie GR, Chen D (2007) Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol, 22(8):1178-1182
  • Wilhelm SM, Carter C, Tang L, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64(19):7099-7109
  • Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW (2008) Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol, 49(5):523-529
  • Tsuchiya K, Asahina Y, Matsuda S, et al. (2014) Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer, 120(2):229-237
  • Parvinian A, Casadaban LC, Hauck ZZ, van Breemen RB, Gaba RC (2015) Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. Diagn Interv Radiol (Ank), 21(3):235-240
  • Park JW, Koh YH, Kim HB, et al. (2012) Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol, 56(6):1336-1342
  • Muftuoglu MA, Aktekin A, Ozdemir NC, Saglam A (2006) Liver injury in sepsis and abdominal compartment syndrome in rats. Surg Today, 36(6):519-524
  • Lo CM, Ngan H, Tso WK, et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 35(5):1164-1171
  • Llovet JM, Ricci S, Mazzaferro V, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359(4):378-390
  • Llovet JM, Pena CE, Lathia CD, et al. (2012) Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res, 18(8):2290-2300
  • Liu LP, Ho RL, Chen GG, Lai PB (2012) Sorafenib inhibits hypoxiainducible factor-1alpha synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res, 18(20):5662-5671
  • Liu L, Chen H, Wang M, et al. (2014) Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PloS one, 9(3):e91124
  • Gaba RC, Yap FY, Martinez EM, et al. (2013) Transarterial sorafenib chemoembolization: preliminary study of technical feasibility in a rabbit model. J Vasc Interv Radiol, 24(5):744-750
  • Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF (2015) Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. Radiology, 277(2):594-603
  • Cheng AL, Kang YK, Chen Z, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol, 10(1):25-34
  • Chatziioannou AN, Siskos AP, Loxas D, et al. (2013) Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study. J Vasc Interv Radiol, 24(11):1657-1663 e1651